NYtor - partner in smart molecular diagnostic assay development

New Developments 

SuperSelective primers (PHRI, New Jersey Medical School, Rutgers University)

Detection of rare mutant cancer cells in a background of extremely abundant wild-type cells.
SuperSelective primers, by virtue of their unique design, employ thermodynamic and kinetic principles that enable the routine quantitation of as few as 10 mutant molecules in samples containing 1,000,000 wild-type molecules, even if the mutation is only a single-nucleotide polymorphism. The early detection of relevant somatic mutations has multiple uses, including:


  • detection of cancer at a treatable stage in patients who inherit genes that make cancer more likely
  • detection of mutations to benign cancer cells that indicate that they can now metastasize
  • measurement of the abundance of cancer cells after treatment to determine whether potentially toxic drugs need to be administered
  • determination during cancer surgery as to whether adjacent tissues can be spared
  • determination as to whether drug-resistant cancer cells have arisen during treatment, so that therapy can be adjusted.

  • Additional information on SuperSelective primers:

    • PLOS ONE 11, e0156546 Multiplex real-time PCR assays that measure the abundance of extremely rare mutations associated with cancer. Vargas et al (2016)


    Mobile Lab / Point-of-Care (BioMeme)

    A smartphone-based DNA & RNA detection platform – no lab necessary

    Biomeme makes a mobile, field-based platform for performing real-time PCR, RT-PCR, and isothermal molecular analysis. The one3™ thermocycler runs up to six tests on a single battery charge, weighs only 1.2 pounds, and can sync all results with a web portal that can be accessed remotely for real-time monitoring of test results and further analysis. While the one3™ is highly configurable and easy to port assays onto, Biomeme also offers fully optimized field kits serving the human health, biothreat, and environmental markets.